45 related articles for article (PubMed ID: 38461615)
21. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
Koschmieder S
Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
[TBL] [Abstract][Full Text] [Related]
22. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
23. New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options.
Penna D
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833399
[TBL] [Abstract][Full Text] [Related]
24. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
25. Novel therapeutic strategies for essential thrombocythemia/polycythemia vera.
Yoon SY; Won JH
Blood Res; 2023 Apr; 58(S1):83-89. PubMed ID: 37105562
[TBL] [Abstract][Full Text] [Related]
26. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
Falanga A; Marchetti M; Schieppati F
Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
[TBL] [Abstract][Full Text] [Related]
27. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
28. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
29. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
30. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
31. Are MPNs vascular diseases?
Finazzi G; De Stefano V; Barbui T
Curr Hematol Malig Rep; 2013 Dec; 8(4):307-16. PubMed ID: 24037420
[TBL] [Abstract][Full Text] [Related]
32. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
[TBL] [Abstract][Full Text] [Related]
33. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
[TBL] [Abstract][Full Text] [Related]
34. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
35. A clinical update in polycythemia vera and essential thrombocythemia.
Tefferi A; Solberg LA; Silverstein MN
Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
[TBL] [Abstract][Full Text] [Related]
36. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
37. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
Barbui T; De Stefano V
Curr Hematol Malig Rep; 2021 Oct; 16(5):455-463. PubMed ID: 34586561
[TBL] [Abstract][Full Text] [Related]
38. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
39. Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
How J; Story C; Connors JM
Postgrad Med; 2021 Jun; 133(5):508-516. PubMed ID: 33480813
[TBL] [Abstract][Full Text] [Related]
40. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.
Andreescu M; Andreescu B
Cureus; 2024 Mar; 16(3):e56008. PubMed ID: 38606222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
